Objective:To observe and compare the efficacy

safety and turnover of plasma exchange and hemoperfusion in treating patients of chronic hepatitis with hyperbilirubinemia.Methods:This is a retrospective study.85 patients with hyperbilirubinemia were treated with plasma exchange and 68 patients with hyperbilirubinemia were treated with hemoperfusion.The clinical symptoms

liver function

bilirubin and prothrombin time activity were compared before and after the treatment in one group

and between the two treatment groups

were examined.Adverse effects were observed in the same time.Results:After plasma exchange

bilirubin decreased significantly;prothrombin time activity and albumin increased significantly(541.68±186.94 VS 337.65±130.52

40.50±19.32 VS 55.29±19.45

30.12±4.24 VS 34.57±3.17).After hemoperfusion

bilirubin decreased;prothrombin time activity and albumin decreased but not significantly(482.69±189.36 VS 473.58±183.57

41.63±19.85 VS 43.03±20.85

30.86±4.31 VS 30.26±3.48).Compared with hemoperfusion

bilirubin

prothrombin time activity and albumin in plasma exchange had more significant change(204.03±102.04 VS 9.11±87.46

-14.79±16.20 VS -1.40±12.78

-1.45±20.83 VS 0.60±3.58

P<0.05).Both treatment affected blood routine test.Potassium and urea nitrogen increased but within normal range.Conclusions:Plasma exchange and hemoperfusion can effectively alleviate clinical symptoms

improve liver function and are effective treatments for patients of chronic hepatitis with hyperbilirubinemia without heavy side effects

especially plasma exchange.